


# A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

## Graphical abstract



## Authors

Xilin Wu, Lin Cheng, Ming Fu, ..., Qinxue Hu, Yalan Liu, Zhiwei Wu

## Correspondence

liuyi@wh.iov.cn (Y.L.),  
wzwh@nju.edu.cn (Z.W.)

## In brief

Wu et al. report Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> with a heterotrimeric bispecific configuration, which exhibits potent neutralization potency against SARS-CoV-2 and its variants, including the prevalent Delta variant, *in vitro* and provides *in vivo* protection against SARS-CoV-2 infection in hACE2 transgenic mice by intranasal delivery.

## Highlights

- We describe a heterotrimeric configuration of Nb-Nb<sub>H</sub>-Nb (Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>)
- Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibits improved viral inhibition and half-life
- Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> provides ultrapotent neutralization against variants Alpha and Delta
- Intranasal delivery of Nbs protects SARS-CoV-2 infection in hACE2 transgenic mice



## Article

# A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Xilin Wu,<sup>1,2,12</sup> Lin Cheng,<sup>3,12</sup> Ming Fu,<sup>4,5,12</sup> Bilian Huang,<sup>1</sup> Linjing Zhu,<sup>2</sup> Shijie Xu,<sup>1,2</sup> Haixia Shi,<sup>6</sup> Doudou Zhang,<sup>2</sup> Huanyun Yuan,<sup>2</sup> Waqas Nawaz,<sup>1</sup> Ping Yang,<sup>4,7</sup> Qinxue Hu,<sup>4,8</sup> Yalan Liu,<sup>4,\*</sup> and Zhiwei Wu<sup>9,10,11,13,\*</sup>

<sup>1</sup>Center for Public Health Research, Medical School, Nanjing University, Nanjing, People's Republic of China

<sup>2</sup>Department of Antibody, Abrev Biotechnology Co., Ltd., Nanjing, People's Republic of China

<sup>3</sup>Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, People's Republic of China

<sup>4</sup>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People's Republic of China

<sup>5</sup>Department of Gastroenterology, Guangzhou Women and Children's Medical Center, Guangzhou 510623, China

<sup>6</sup>Department of Antibody, Y-clone Medical Science Co. Ltd., Suzhou, People's Republic of China

<sup>7</sup>Savaid Medical School, University of Chinese Academy of Sciences, Beijing, People's Republic of China

<sup>8</sup>Institute for Infection and Immunity, St George's University of London, London SW17 0RE, UK

<sup>9</sup>School of Life Sciences, Ningxia University, Yinchuan, People's Republic of China

<sup>10</sup>Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing, People's Republic of China

<sup>11</sup>State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, People's Republic of China

<sup>12</sup>These authors contributed equally

<sup>13</sup>Lead contact

\*Correspondence: liuyi@wh.iov.cn (Y.L.), wzhw@nju.edu.cn (Z.W.)

<https://doi.org/10.1016/j.celrep.2021.109869>

## SUMMARY

The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19. Here, we characterize several receptor binding domain (RBD)-specific Nbs isolated from an Nb library derived from an alpaca immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S); among them, three Nbs exhibit picomolar potency against SARS-CoV-2 live virus, pseudotyped viruses, and circulating SARS-CoV-2 variants. To improve their efficacy, various configurations of Nbs are engineered. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>, a trimer constituted of three Nbs, is constructed to be bispecific for human serum albumin (HSA) and RBD of SARS-CoV-2. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibits single-digit ng/ml neutralization potency against the wild-type and Delta variants of SARS-CoV-2 with a long half-life *in vivo*. In addition, we show that intranasal administration of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> provides effective protection for both prophylactic and therapeutic purposes against SARS-CoV-2 infection in transgenic hACE2 mice. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> is a potential candidate for both the prevention and treatment of SARS-CoV-2 through respiratory administration.

## INTRODUCTION

As of February 1<sup>st</sup>, 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 100 million confirmed cases and over 2.2 million deaths globally. The containment of the expanding coronavirus disease 2019 (COVID-19) pandemic needs multiple countermeasures. Prophylactic vaccines have been recently approved (Dai and Gao, 2020), and a number of SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) that target the receptor binding domain (RBD) of the spike protein (Baum et al., 2020; Ju et al., 2020; Liu et al., 2020; Rogers et al., 2020; Shi et al., 2020) were identified, which could be developed as either therapeutic or prophylactic agents.

In addition to conventional antibodies, camelids also generate heavy-chain-only antibodies (HCAbs), constituting a single variable domain (nanobody [Nb]) specific for binding antigens (Hamers-Casterman et al., 1993). This single variable domain, referred as a single-domain antibody, variable heavy-chain domains of heavy-chain antibody (VHH), or Nb, has higher affinity, thermal stability, and chemostability than most antibodies (Jovčevska and Muyldermans, 2019; Steeland et al., 2016) and can be constructed easily into multivalent formats devoid of Fc, which will overcome potential deleterious antibody-dependent enhancement (ADE) of infection observed in some viral infections, including dengue virus, HIV, and SARS-CoV (Luo et al., 2018; Taylor et al., 2015; Tirado and Yoon, 2003). Their favorable biophysical properties have led to the



development of several Nbs as therapeutics against viral infection, such as severe fever with thrombocytopenia syndrome virus (SFTSV) (Wu et al., 2020a) and respiratory syncytial virus (RSV) (Cunningham et al., 2020; Detalle et al., 2015; Van Heeke et al., 2017).

SARS-CoV-2 is transmitted by the upper respiratory tract (Zhou et al., 2020), and an analysis of clinical specimens showed that SARS-CoV-2 was detected with the highest viral copies in multiple sites of the respiratory tract, whereas few viral copies are in the blood (Wang et al., 2020). These data indicate that biotherapeutic agents directly delivered by the respiratory route to the sites of infection would be an attractive alternative to systemic routes of administration. Parenteral inoculation of a biotherapeutic antibody is a particularly ineffective way to deliver drugs to the respiratory tract. Indeed, a study on mepolizumab (anti-interleukin-5 mAb) demonstrated that only 0.2% of the dose administered reached the lung by systemic administration (Hart et al., 2001). In addition, the therapeutic effect of pulmonary delivery of human immunoglobulins for controlling RSV in cotton rats was shown to be 160 times more effective than that by the parenteral administration (Prince et al., 1987). Thus, pulmonary delivery may be superior to parenteral administration for the treatment of respiratory tract infections.

A key requirement for pulmonary delivery is the stability of the biologic product so that it endures the degrading environment, and thus, the drug will have to be formulated to maintain its structural integrity and bioactivity through the upper respiratory tract and the lungs. Nbs are delivered directly to the lungs by an inhaler given their small size, simple and robust structure, high thermal stability, and solubility. For instance, ALX-0171, a homotrimeric Nbs, is highly effective at reducing nasal and lung RSV titers by the pulmonary administration of inhalation (Cunningham et al., 2020; Detalle et al., 2015).

To date, several Nbs against SARS-CoV-2 were reported for their *in vitro* activities; however, only few Nbs have recently been evaluated *in vivo* (Dong et al., 2020; Hanke et al., 2020; Huo et al., 2020; Nambulli et al., 2021; Pymm et al., 2021; Schoof et al., 2020; Wu et al., 2020b; Xiang et al., 2020). In the current report, anti-sera specific for RBD were elicited by immunizing an alpaca with the SARS-CoV-2 spike glycoprotein (S). Nbs specific for RBD were isolated from a phage library displaying Nbs. We identified three Nbs exhibiting potent neutralization activity against live virus and a panel of SARS-CoV-2 pseudotyped viruses. To improve the efficacy and stability, various configurations of Nbs were engineered. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>, a bispecific format constituted of three Nbs, was constructed to be trivalent and bispecific for the RBD of SARS-CoV-2 and human serum albumin (HSA). This bispecific antibody exhibited potent inhibitory activity against the wild type and variants of SARS-CoV-2, including the currently circulating variants, such as the predominant mutant viruses in the United Kingdom and South Africa with an N501Y mutation. In addition, we showed that intranasal (i.n.) administration of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> provided 100% protection in both the prevention and treatment of SARS-CoV-2-infected transgenic hACE2 mice. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> is a potential candidate for both the prevention and treatment of SARS-CoV-2.

## RESULTS

### Anti-sera response elicited by the S protein


One alpaca was immunized with the extracellular domain of the SARS-CoV-2 spike protein (S1+S2 ECD, S) (Figure S1A). Compared to the pre-immunized serum (blank serum), the anti-serum after the third immunization exhibited specific serologic activities against SARS-CoV-2 S and RBD proteins with binding titers of  $2.19 \times 10^6$  and  $7.29 \times 10^4$ , respectively (Figures S1B and S1C). The immunized serum showed potent neutralization activity against the pseudotyped SARS-CoV-2 with a half-maximal neutralization dilution (ND<sub>50</sub>) of  $\sim 9,600$  (Figure S1D). These data indicate that potent anti-serum specific for RBD with robust neutralization against SARS-CoV-2 was induced in the immunized alpaca.

### Isolation of Nbs with potent neutralization activity against SARS-CoV-2

To isolate monoclonal Nbs, a C9-Nb library, a phage library displaying Nbs from the immunized alpaca, was constructed with a size of  $2.0 \times 10^9$ , 100% sequence diversity, and 96% in-frame rate as validated by PCR and sequencing (Figure S2A). Nbs specific for the SARS-CoV-2 S protein were isolated through three rounds of biopanning on the C9-Nb phage library by the S protein. The panned library was analyzed by phage ELISA for binding with the S protein, and we found an incremental increase of the optical density 450 (OD<sub>450</sub>) readout from 0.79 before enrichment to 1.6, 2.4, and 2.8 after the first, second, and third rounds of enrichment, respectively (Figure S2B), indicating successful enrichment. To verify whether the enriched library contained specific S-reactive phages, 40 and 46 clones were selected from the libraries after the second and third rounds, respectively, of enrichment for single-phage ELISA. The percentage of positive clones was 57.5% and 69.6% for the second and third rounds, respectively (Figure S2C). Among these positive binders, 21 distinct Nb sequences were identified according to the sequencing results (Table S1). For a further characterization, these 21 Nbs were expressed in mammalian cells by fusing the Nb gene with a human Fc1, which was cloned into the pCDNA3.4 vector to express the Nb-Fc antibody (named as Nb-Fc) (Figure S3A). ELISA results showed that all 21 Nb-Fcs reacted with the S protein; among them, 14 Nb-Fcs displayed specific binding with the SARS-CoV-2 RBD protein (Figure S3B). These results were validated by bio-layer interferometry (BLI), wherein 14 Nb-Fcs exhibited specific binding to RBD with dissociation constant (K<sub>D</sub>) values ranging from 4.25 to 37.6 nM (Figures S3C and S3D). A neutralization analysis showed potent inhibition of pseudotyped SARS-CoV-2 by culture supernatants of RBD-specific Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc (Figure S3E).

### Epitope analysis of Nb-Fcs

The purified Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc exhibited dose-dependent binding with the RBD protein by ELISA (Figure S4A). In addition, Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc likely reacted with the conformational structure, as their bindings with reduced RBD protein were almost completely abolished (Figure S4B). The kinetic binding of Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc with the RBD protein ranged from a K<sub>D</sub> of 1.13 to 1.76 nM, indicating



**Figure 1. Characterizing the potency and breadth of neutralization conferred by Nb-Fcs**

(A and B) The neutralization potency of Nb-Fcs was detected based on an authentic SARS-CoV-2 plaque reduction neutralization test (A) and the pseudotyped SARS-CoV-2 neutralization assay (B). SNB02 was taken as a negative isotype control antibody (Nb fused with human Fc1).

(legend continued on next page)

tightly clustered binding characteristics (Figures S4C–S4E), which was substantiated by the superimposed ELISA binding curves (Figure S4A). These three Nb-Fcs were next evaluated for epitope specificity in a competition assay by BLI by using the RBD protein as a capture antigen. The results revealed that the pre-bound Nb-Fcs efficiently blocked the further binding of the other two Nb-Fcs to the RBD protein, suggesting that all three Nb-Fcs likely recognize an overlapping epitope (Figures S5A–S5C). Together, Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc recognize a quaternary and overlapping epitope on RBD with nanomolar affinities.

### Nb-Fcs exhibit potent neutralization against SARS-CoV-2 and variants

The neutralizing activity of Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc against SARS-CoV-2 live virus was investigated in Vero E6 cells. All three Nb-Fcs exhibited potent neutralization activity with the half maximal inhibitory concentration (IC<sub>50</sub>) values in the range of 0.0033–0.0068 μg/ml (41.3–75 pM) and IC<sub>90</sub> in the range of 0.0156–0.0235 μg/ml (195–293.8 pM) (Figure 1A; Figures S6A–S6E). The neutralizing potency was validated by the SARS-CoV-2 pseudovirus neutralization assay with consistent results, with IC<sub>50</sub> values of 0.0008, 0.0018, and 0.0023 μg/ml (10, 22.5, and 28.8 pM), respectively (Figure 1B; Table S2). The IC<sub>50</sub> values are comparable to those of the ultrapotent neutralizing antibodies or Nbs reported (Robbiani et al., 2020; Rogers et al., 2020; Schoof et al., 2020; Xiang et al., 2020; Zost et al., 2020). The cross neutralization of these Nbs against other coronaviruses was also evaluated in a pseudovirus assay, and the results showed that these three Nb-Fcs did not inhibit either Middle East Respiratory Syndrome (MERS)-CoV or SARS-CoV pseudovirus (Figures 1C and 1D) but inhibited 15 representative variants of SARS-CoV-2 that are identified to represent over 7,000 distinct viral genomes (Baum et al., 2020). As expected, Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc also inhibited the replication of recently arising SARS-CoV-2 variants with a D614G mutation with similar potency (Figures 1E–1G; Table S2). This evidence demonstrates the neutralizing activity of the Nb-Fcs against multiple SARS-CoV-2 variants and suggests that the Nb-Fcs target at a highly conserved epitope on the RBD protein. Taken together, these three Nb-Fcs exhibited excellent neutralization potency against the original and the representative variants of SARS-CoV-2, whereas they did not inhibit MERS-CoV and SARS-CoV infection. Given the overlapped epitope recognized by the three Nb-Fcs, Nb<sub>15</sub>-Fc with the highest neutralization potency was selected for further investigation.

### Construction and characterization of multiple-valent Nb<sub>15</sub>S

To improve potency, prolong *in vivo* half-life, and avoid potential Fc-mediated ADE, a number of dimeric and trimeric configurations of Nbs were engineered. Monomer (1 × Nb<sub>15</sub>), homodimer

(2 × Nb<sub>15</sub>), homotrimer (3 × Nb<sub>15</sub>), and homotetramer (4 × Nb<sub>15</sub>) formats were constructed and analyzed by BLI. The binding of these constructs to the RBD protein showed an increasing K<sub>D</sub> ranging from 12 to <0.001 nM as the valence increased (Figures 2A and 2B). Multivalent formats of Nb<sub>15</sub> were evaluated for neutralization against pseudotyped SARS-CoV-2 infection *in vitro*. Monomeric 1 × Nb<sub>15</sub> exhibited low inhibitory activity with an IC<sub>50</sub> of 307 ng/ml (2.3 nM), whereas the bi-, tri-, and tetra-valent configurations exhibited higher neutralization potency than the monomer but comparable potency among the multimers with IC<sub>50</sub> values of 2.8, 3.5, and 2.3 ng/ml (11, 9.0, and 4.3 pM), respectively (Figure 2C; Table 1), suggesting that increasing valence does not confer improved anti-viral activity. As such, 3 × Nb<sub>15</sub> was selected for further functional exploration.

### Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>, heterotrimeric and bispecific for RBD and HSA, exhibits potent neutralization against SARS-CoV-2


In order to improve Nb<sub>15</sub> efficacy and stability *in vivo*, we constructed bispecific Nbs consisting of one Nb specific for HSA (Nb<sub>H</sub>) developed by our lab and one or two Nb<sub>15</sub>S specific for RBD with (G4S)<sub>3</sub> as the linker between each Nb (Figure 3A) and analyzed their binding and viral inhibitory activities. In addition to the heterodimeric configuration of Nb-Nb<sub>H</sub> that was previously reported (Van Roy et al., 2015), various configurations of Nbs were engineered as depicted in Figure 3A. An ELISA analysis showed that all combinations containing Nb<sub>15</sub> reacted with the RBD protein; among them, heterotrimeric Nb<sub>15</sub>-Nb<sub>15</sub>-Nb<sub>H</sub>, Nb<sub>H</sub>-Nb<sub>15</sub>-Nb<sub>15</sub>, and Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited better binding with the RBD protein than heterodimeric Nb<sub>15</sub>-Nb<sub>H</sub> and Nb<sub>H</sub>-Nb<sub>15</sub> configurations (Figures 3A and 3B). Furthermore, Nb<sub>15</sub>-Nb<sub>H</sub>, Nb<sub>H</sub>-Nb<sub>15</sub>-Nb<sub>15</sub>, and Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> were the top HSA binders as compared to other configurations (Figures 3A and 3C). Bispecific Nbs in various configurations were tested for the inhibition of SARS-CoV-2 infection; among them, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited the most potent neutralization of the pseudotyped virus with an IC<sub>50</sub> of 0.4 ng/ml (9.0 pM) (Figure 3D; Table 1). We next compared Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> with homotrimer Nbs (3 × Nb<sub>15</sub>) or Nb-Fc for their binding and anti-viral activities and found that 3 × Nb<sub>15</sub>, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>, and Nb<sub>15</sub>-Fc exhibited comparable potency with IC<sub>50</sub> values of 0.4, 0.4, and 0.9 ng/ml (9.0, 9.0, and 11.3 pM), respectively (Figure 3E; Table 1).

### Pharmacokinetics and delivery of Nb constructs

Given that 3 × Nb<sub>15</sub>, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>, and Nb<sub>15</sub>-Fc exhibited comparable neutralization activity (Figure 3E), these three constructs were evaluated for their *in vivo* pharmacokinetic activity. The results showed that, when administrated by *i.n.*, intraperitoneal (*i.p.*), or intravenous (*i.v.*) routes, 3 × Nb<sub>15</sub> was rapidly metabolized as compared to Nb<sub>15</sub>-Fc and Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> (Figures 4A–4C); therefore, 3 × Nb<sub>15</sub> was ruled out for further analysis. To determine the tissue distribution

(C–G) Nb-Fcs were tested for the neutralization against the pseudovirus infection of SARS-CoV (C) and MERS-CoV (D). The pseudovirus of 15 SARS-CoV-2 variants identified from circulating viral sequences were tested to evaluate the neutralization potency conferred by Nb<sub>15</sub>-Fc (E), Nb<sub>22</sub>-Fc (F), and Nb<sub>31</sub>-Fc (G). The y axis shows the ratio of IC<sub>50</sub> of indicated SARS-CoV-2 variant/IC<sub>50</sub> of SARS-CoV-2 wild-type (WT) conferred by Nb-Fcs. The names of SARS-CoV-2 variants with an amino acid point mutation based on the wild type of SARS-CoV-2 are indicated. Data are represented as mean ± SEM. All experiments were repeated at least twice.





**Figure 2. Characterization of Nb<sub>15</sub>s with multivalent or various formats**

(A) The binding curve of multivalent Nb<sub>15</sub>s with RBD protein detected by BLI.

(B) The table summary of the binding of Nb<sub>15</sub>s with RBD protein tested by BLI.

(C) Multivalent Nb<sub>15</sub>s and various formats were evaluated for neutralization potency against pseudotyped SARS-CoV-2 infection.

of Nbs, YF<sup>®</sup>750 SE-labeled Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> (Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>-YF750) were administered by i.n., i.p., or i.v. routes in mouse model. The results revealed that the fluorescence in trachea could be detected only when Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>-YF750 was administered i.n. Furthermore, the fluorescence intensity was higher in lungs when Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>-YF750 was administered i.n. ( $6.9 \times 10^{10}$  ph/s) than that when administered i.p. or i.v. ( $1.4 \times 10^{10}$  and  $4.3 \times 10^{10}$  ph/s, respectively) (Figures 4D and 4E). In addition, the results also showed that Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> could reach lungs and was sustained for more than 168 h (7 days) when administrated i.n.; in contrast, the fluorescence could only be detected between 1 and 2 h after i.p. infusion (Figures 4F and 4G). These results suggest that i.n. administration of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> will be a favorable route for the antibody to reach the nasopharynx and lungs where SARS-CoV-2 replicates. Therefore, to avoid the potential ADE associated by Fc in the Nb-Fc, we selected Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> for further efficacy evaluation *in vivo*.


#### **In vitro characterization of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>**

Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> was further characterized *in vitro*. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited specific binding to RBD and HSA with K<sub>D</sub> values of 0.54 and 7.7 nM, respectively (Figures 5A and 5B). In addition, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> also showed specific binding with murine serum albumin (MSA) with K<sub>D</sub> values of 14.5 nM (Figure S7), indicating that mice can be used as an animal model to investigate the half-life of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>. Furthermore, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited sub-ng/ml (pM) potency against both the wild type (WHU01) and 18 out of 19 currently circulating SARS-CoV-2 mutant variants tested (Figure 5C; Table S2). Importantly, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> showed comparable potency against the pseudotyped SARS-CoV-2 variants with D614G and N501Y mutations that circulate predominantly in the United

Kingdom and South Africa. Moreover, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited neutralization against pseudotyped variants of the wild type, Alpha (N501Y), Epsilon (L452R), and Delta (L452R and T478K) with IC<sub>50</sub> values of 0.4 ng/ml, 0.26 ng/ml, 88.95 ng/ml, and 5.16 ng/ml (9.0, 5.9, 2001, and 116 pM), respectively. However, it failed to neutralize Gamma (E484K and K417T), Beta (E484K and K417N), and other circulating variants (Figure 5D). Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> also showed excellent thermal stability by retaining 100% and 83% activities even at 70°C and 80°C for 1 h, respectively (Figures 5E and 5F; Table S3). Furthermore, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> retained 100% activity after aerosolization, indicating the potential application as a nebulized drug (Figures 5E and 5F; Table S3).

**Table 1. Summary of various Nbs inhibiting pseudotyped SARS-CoV-2**

Nbs	IC <sub>50</sub> (mean ± SD μg/ml)	IC <sub>80</sub> (mean ± SD μg/ml)	IC <sub>90</sub> (mean ± SD μg/ml)
1 × Nb <sub>15</sub>	0.3074 ± 0.0237	0.5059 ± 0.0699	0.622 ± 0.0969
2 × Nb <sub>15</sub>	0.0003 ± 0	0.0008 ± 0.0001	0.0011 ± 0.0001
3 × Nb <sub>15</sub>	0.0004 ± 0	0.001 ± 0	0.0014 ± 0.0001
4 × Nb <sub>15</sub>	0.0002 ± 0.0001	0.0008 ± 0.0001	0.0011 ± 0.0002
Nb <sub>15</sub> -Nb <sub>H</sub>	0.5529 ± 0.0889	1.071 ± 0.1754	1.374 ± 0.2263
Nb <sub>H</sub> -Nb <sub>15</sub>	0.1974 ± 0.004	0.3469 ± 0.0533	0.4344 ± 0.0822
Nb <sub>15</sub> -Nb <sub>15</sub>	0.0251 ± 0.0058	0.0419 ± 0.0051	0.0517 ± 0.0047
Nb <sub>H</sub> -Nb <sub>15</sub> -Nb <sub>15</sub>	0.0008 ± 0.0001	0.0017 ± 0.0003	0.0022 ± 0.0004
Nb <sub>15</sub> -Nb <sub>H</sub> -Nb <sub>15</sub>	0.0004 ± 0	0.0009 ± 0	0.0013 ± 0
Nb <sub>15</sub> -Fc	0.0009 ± 0.0001	0.0019 ± 0.0001	0.0025 ± 0.0002



**Figure 3. Design and characterization of bispecific Nbs**

(A) Various Nbs at 37  $\mu$ g/ml binding to RBD, and HSA protein identified by ELISA.

(B and C) The binding curve of Nbs interacting with RBD protein (B) and HSA protein (C) identified by ELISA.

(D) The neutralizing potency of bispecific Nbs against SARS-CoV-2 pseudovirus measured by neutralization assay.

(E) The neutralizing potency of  $Nb_{15}$ -Fc, 3  $\times$   $Nb_{15}$ , and  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  against SARS-CoV-2 pseudovirus infection measured by neutralization assay.

Data are represented as mean  $\pm$  SEM. All experiments were repeated at least twice.

group,  $n = 5$ ) but failed to provide complete protection under the same conditions as  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  (Figures 6B–6D). Furthermore, a histopathological analysis of lung tissues showed that SARS-CoV-2 challenge induced severe lung lesions, as shown by the infiltration of inflammatory cells and thickened alveolar septa (Figure 6D). In contrast, the lungs of the mice receiving  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  or  $Nb_{15}$ -Fc treatment showed no apparent pathological changes (Figure 6D). Together,  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  at an average of 10 mg/kg administrated i.n. 24 h before or 1 h after challenge provided complete protection against SARS-CoV-2 infection and significantly inhibited SARS-CoV-2 replication when the antibody was administrated 24 h postinfection.  $Nb_{15}$ -Fc used at an average of 10 mg/kg administrated i.n. 1 h after challenge significantly reduced viral load but failed to provide complete protection. We noted that those mice receiving  $Nb_{15}$ s treatment showed less weight loss than the control mice but did not achieve a statistical difference (Figures 6E and 6F). These results indicate that  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$ , when used early during infection, conferred a higher protection efficacy than that used at a later time point. In summary, the  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  configuration administrated i.n. was superior to  $Nb_{15}$ -Fc and exhibited both prophylactic and therapeutic efficacy against SARS-CoV-2 challenge.




### In vivo anti-SARS-CoV-2 activity of $Nb_{15}$ - $Nb_H$ - $Nb_{15}$

To evaluate the efficacy of  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  *in vivo*, HACE2 transgenic mice were challenged with  $1 \times 10^5$  PFU SARS-CoV-2 (Strain IVCAS 6.7512; Zhou et al., 2020), and  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  was administrated i.n. either before or after viral challenge for prophylactic or therapeutic efficacy (Figure 6A). Viral RNA was detected in the lungs of control mice ( $6.28 \times 10^5$  copies/mg on average in SARS-CoV-2 group,  $n = 5$ ) and the isotype-treated control mice ( $7.8 \times 10^4$  copies/mg on average in isotype group,  $n = 3$ ). For the prophylactic group, no viral RNA or infected cells were detected in 100% (5/5) of the mice when 250- $\mu$ g (average of 10 mg/kg)  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  was administrated i.n. 24 h before SARS-CoV-2 infection ( $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  -24h group,  $n = 5$ ), as evidenced by real-time PCR and immunofluorescence staining (Figures 6B–6D). A total of 100% of mice were also completely protected when 250- $\mu$ g  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  as administrated i.n. 1 h postinfection, as no viral RNA and infected cells were detected in all infected mice ( $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  1-h group,  $n = 5$ ) (Figures 6B–6D). Significantly lower SARS-CoV-2 RNA copies ( $9.98 \times 10^3$  copies/mg on average) were detected in the lungs of the mice treated with  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  i.n. 24 h postinfection ( $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  24 h group,  $n = 5$ ) than those in the control mice ( $6.28 \times 10^5$  copies/mg on average in SARS-CoV-2 group and  $7.8 \times 10^4$  copies/mg in isotype control) (Figures 6B–6D).  $Nb_{15}$ -Fc inhibited viral replication and reduced the viral copy number (average of  $7.59 \times 10^3$  copies/mg in  $Nb_{15}$ -Fc 1-h

group,  $n = 5$ ) but failed to provide complete protection under the same conditions as  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  (Figures 6B–6D). Furthermore, a histopathological analysis of lung tissues showed that SARS-CoV-2 challenge induced severe lung lesions, as shown by the infiltration of inflammatory cells and thickened alveolar septa (Figure 6D). In contrast, the lungs of the mice receiving  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  or  $Nb_{15}$ -Fc treatment showed no apparent pathological changes (Figure 6D). Together,  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  at an average of 10 mg/kg administrated i.n. 24 h before or 1 h after challenge provided complete protection against SARS-CoV-2 infection and significantly inhibited SARS-CoV-2 replication when the antibody was administrated 24 h postinfection.  $Nb_{15}$ -Fc used at an average of 10 mg/kg administrated i.n. 1 h after challenge significantly reduced viral load but failed to provide complete protection. We noted that those mice receiving  $Nb_{15}$ s treatment showed less weight loss than the control mice but did not achieve a statistical difference (Figures 6E and 6F). These results indicate that  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$ , when used early during infection, conferred a higher protection efficacy than that used at a later time point. In summary, the  $Nb_{15}$ - $Nb_H$ - $Nb_{15}$  configuration administrated i.n. was superior to  $Nb_{15}$ -Fc and exhibited both prophylactic and therapeutic efficacy against SARS-CoV-2 challenge.


### DISCUSSION

In this study, three potent neutralizing Nb-Fcs were isolated from a phage display platform derived from an alpaca immunized with the SARS-CoV-2 S protein. These three RBD-specific Nb-Fcs exhibited potent inhibitory activities against 15 mutant variants of pseudotyped SARS-CoV-2 with  $IC_{50}$  values in the range of 0.5–2.8 ng/ml (Figures 1E–1G; Table S2). The  $IC_{50}$  values are comparable to those of the most potent neutralizing antibodies or Nbs reported (Robbiani et al., 2020; Rogers et al., 2020; Schoof et al., 2020; Xiang et al., 2020; Zost et al., 2020). These



(legend on next page)





**Figure 5. Functional characterization of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>**

(A and B) Kinetic binding curve of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> at the concentrations 300 nM, 100 nM, 33.3 nM, 11.1 nM, 3.7 nM, and 1.2 nM with RBD (A) and HSA (B) by BLI. Binding curves are colored black, and the fit of the data to a 1:1 binding model is colored red.

(C) The neutralization curve of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> inhibiting SARS-CoV-2 pseudovirus and its variants with amino acid point mutation as indicated. WT, wild-type SARS-CoV-2 pseudovirus of 2019-nCoV WHU01 (accession ID: MN988668.1).

(D) The neutralization curve of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> inhibiting SARS-CoV-2 pseudovirus of circulating variants. WT was indicated as in (C). Alpha, B.1.1.7 variant reported in United Kingdom; Beta, B.1.351 variant reported in S. Africa; Gamma, P.1 variant reported in Brazil; Epsilon, B.1.429 variant reported in California; Delta, B.1.617.2 variant reported in India; Eta, B.1.525 variant reported in UK; Iota, B.1.526 variant reported in New York; Kappa, B.1.617.1 variant reported in India.

(E) Binding curve of RBD with Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> at the concentration of 133 nM (5 µg/ml) before (no treatment, WT) or after aerosolization (Aero) or after treatment at the indicated temperature, including 37°C, 50°C, 60°C, 70°C, 80°C, and 90°C for 1 h. Binding curves are colored black, and the fit of the data to a 1:1 binding model is indicated.

(F) Snapshot of the relative binding response of the highest binding response at the indicated condition/the highest response of RBD with Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> in the no-treatment condition (WT). The relative binding of WT was normalized as 100%. Data are represented as mean ± SEM. All experiments were repeated at least twice.

15 representative variants of SARS-CoV-2 are identified to represent over 7,000 distinct viral genomes (Baum et al., 2020). As expected, recently arising variants with a D614G mutation were also sensitive to the neutralization by Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc, and Nb<sub>31</sub>-Fc with similar sensitivity (Figures 1E–1G; Table S2). This evidence demonstrates the neutralizing activity of these

Nbs against multiple SARS-CoV-2 variants and suggests that the Nb-Fcs target at a highly conserved epitope on the RBD protein.

To improve potency, prolong *in vivo* half-life, and avoid potential Fc-mediated ADE, Nb<sub>H</sub> specific for HSA and MSA was used to construct a trimeric Nb<sub>15</sub> (Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>) for SARS-CoV-2, and

#### Figure 4. Pharmacokinetics of Nb<sub>15</sub>s *in vivo*


(A–C) Bioavailability and T<sub>1/2</sub> (half-life) of Nb<sub>15</sub>s in BALB/c mice. Nb<sub>15</sub> variants were intranasally (i.n.) administered into mice (n = 3, female) at 200 µg (average of 10 mg/kg mice) (A), intraperitoneally (i.p.) administered into mice (n = 3, female) at 400 µg (average of 20 mg/kg mice) (B), and intravascularly (i.v.) administered into mice (n = 3, female) at 400 µg (average of 20 mg/kg mice) (C). Serum concentrations of the Nbs were determined at indicated time points by ELISA. Nb<sub>15</sub> variants are colored as follows: Nb<sub>15</sub>-Fc (red), Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> (orange), and 3 × Nb<sub>15</sub> (cyan). C<sub>max</sub>, maximum observed plasma concentration. Data are represented as mean ± SEM.

(D) Spatial distribution of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>-YF750 1 h after infusion into mice (n = 3 in each group) by i.n., i.p., and i.v. routes was detected by a NightOwl LB 983 system. The middle figure in the red dashed line shows the dissected image of the left mouse in the red dashed line. The right figure shows the organs from dissected mice that were imaged immediately after sacrifice. Tr, trachea; Lu, lung; H, heart; Li, liver; Sp, spleen; St, stomach; I, large and small intestine; Ki, kidneys; B, bladder.

(E) The fluorescence intensity (ph/s) summary of each organ in (D) was quantified and presented as the mean ± SEM.

(F) Pharmacokinetics of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>-YF150 by i.n. administration at the indicated time point. Mice were sacrificed at the indicated time point for the analysis of fluorescence intensity in various organs labeled as in (D). The blue dashed line figure shows the enlarged image of the individual figure indicated by corresponding arrows.

(G) Nude mice (n = 3–6) were administered with Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>-YF750 by the i.n. or i.p. route. The fluorescence intensity at the lung location as shown in the yellow dashed line circle of M02 in (F) was measured at the indicated time point. Data are represented as mean ± SEM.



(legend on next page)

the resulting Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited the highest neutralization potency with the IC<sub>50</sub> value of 0.4 ng/ml among other configurations, including Nb<sub>15</sub>-Nb<sub>H</sub>, a configuration reported earlier (Van Roy et al., 2015). Interestingly, we found that Nb<sub>15</sub>-Nb<sub>H</sub> and Nb<sub>H</sub>-Nb<sub>15</sub> with the same components exhibited distinct neutralization potencies with IC<sub>50</sub> values of 552.3 ng/ml and 197.4 ng/ml, respectively. In addition, Nb<sub>H</sub>-Nb<sub>15</sub>-Nb<sub>15</sub> and Nb<sub>15</sub>-Nb<sub>15</sub>-Nb<sub>H</sub> also displayed distinct neutralization potencies with IC<sub>50</sub> values of 25.1 ng/ml and 8 ng/ml, respectively (Figure 3D; Table 1), indicating that the Nb configuration has an effect on the neutralizing activity. In addition, the heterotrimeric bispecific configuration is superior to the bispecific heterodimer. We also noted that the bi-, tri-, and tetravalent configurations exhibited comparable potency with IC<sub>50</sub> values of 2.8, 3.5, and 2.3 ng/ml (11, 9.0, and 4.3 pM), respectively. The neutralizing potency did not correspond to the valence increase when there are two or more than two Nb<sub>15</sub>s, although monomeric 1 × Nb<sub>15</sub> had a much lower inhibitory activity (Figure 2C; Table 1). We noted that Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> shows higher potency than Nb<sub>H</sub>-Nb<sub>15</sub>-Nb<sub>15</sub>, Nb<sub>15</sub>-Nb<sub>15</sub>-Nb<sub>H</sub>, and all the homomultimers, suggesting that the position of Nb<sub>H</sub> plays important roles in neutralization activity. We speculate that in Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>, Nb<sub>H</sub> may space out the two Nb<sub>15</sub>s to either avoid cross interference with each other or allow better binding of the trimeric Nb to S proteins on the viral particle. Furthermore, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> displayed comparable neutralizing potency as those of Nb<sub>15</sub>-Fc and 3 × Nb<sub>15</sub> and higher neutralization potency and longer half-life than 3 × Nb<sub>15</sub> *in vivo* when delivered via i.n., i.p. or i.v. routes. Altogether, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> was established as a potentially promising construct, suggesting a format of nanobodies with improved potency and half-life *in vivo*.

Importantly, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited neutralizing activities against 18 out of 19 pseudotyped SARS-CoV-2 variants except the E484K mutant variant that we tested. Moreover, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited neutralization against pseudotyped variants of wild type (Wuhan-Hu-01), Alpha (N501Y, B.1.1.7 variant, United Kingdom), Epsilon (L452R, B.1.429 variant, California), and Delta (L452R and T478K, B.1.617.2 variant, India), which has become predominant and contributed to the current wave of infection in many countries. Delta has been designated as a variant of concern (VOC) and is believed to be 60% more transmissible than variant Alpha (Planas et al., 2021). Some mAbs, including bamlanivimab, lost binding to the Spike and no longer neutralized variant Delta (Planas et al., 2021). Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited potent neutralization against variant Delta (IC<sub>50</sub> values of 5.16 ng/ml) with about

20-fold less potent neutralization against Alpha (IC<sub>50</sub> values of 0.26 ng/ml) (Figure 5D). However, it failed to neutralize P.1 (E484K and K417T, Gamma, Brazil), B.1.351 (E484K and K417N, Beta, South Africa), B.1.617.1 (L452R and E484Q, India), and other circulating variants (Figure 5D), suggesting a E484K/Q mutation variant could be resistant to the neutralization of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub>.

Although several neutralizing antibodies against SARS-CoV-2 are in various stages of clinical trials or have been approved as an emergency therapy, most of these antibodies are of limited efficacy. SARS-CoV-2 is present mainly in the nasopharynx and lungs (Gallo et al., 2020; Higgins et al., 2020). Differing from many previously reported therapies with a systemic delivery route, Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> was delivered to the site of infection. Direct administration to the airways is likely to provide faster and more robust antiviral activity in the respiratory tract, where the virus gains entry and replicates (Cunningham et al., 2020; Higgins et al., 2020), as i.n. delivery has been shown to result in fast and efficient drug delivery to the main site of SARS-CoV-2 infection, i.e., the upper and lower respiratory tract (Higgins et al., 2020). Indeed, the therapeutic effect of topical administration of ALX-0171 displayed promising results in reducing the RSV viral load (Cunningham et al., 2020; Detalle et al., 2015). The current study demonstrated the *in vivo* efficacy of Nbs against SARS-CoV-2 infection by i.n. delivery.

In summary, compared to the configurations of Nb-Nb<sub>H</sub>, Nb-Fc, and Nb homotrimer, a potential promising construct of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited a higher neutralization activity and longer half-life *in vivo*. Our results provide a strategy for the construction of multivalent Nbs with improved potency and half-life *in vivo*. Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> exhibited highly potent antiviral activity against a large panel of SARS-CoV-2 clinical variants except E484K/Q mutants. Furthermore, direct delivery of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> to the airways/lungs by the i.n. route proved an effective mode of drug delivery, and the outstanding thermal stability of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> is an additional advantage. We suggest that respiratory delivery of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> is a promising route for the prevention and treatment of SARS-CoV-2 infection and thus warrants further clinical evaluation by i.n. delivery.

## STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

### Figure 6. The efficacy of Nb<sub>15</sub>s evaluated in hACE2 transgenic mice challenged by SARS-CoV-2

(A) Experimental schedule of Nb<sub>15</sub>s in the prevention and treatment of SARS-CoV-2 infection. Bottom, table summary of groups (n = 3–5 mice) with different treatments.

(B) Viral loads in lungs among 7 groups were measured by qRT-PCR. The name of each group in the x axis was indicated as in the table in (A). Each dot represents one mouse. The limit of detection was 3,160 copies/mg referenced to blank control (no-SARS-CoV-2 group).

(C) Sections of lungs were analyzed by immunofluorescence staining by using antibodies specific to SARS-CoV-2 nucleocapsid protein (NP) in red and DAPI (4',6-diamidino-2-phenylindole) for nuclei in blue, respectively. The fluorescence signal intensity of red was taken as a quantitative indicator for viral infection, which was calculated by ImageJ software.

(D) Representative sections of lung in (C) were visualized under the ×20 objective at the indicated scale bar (200 μm). The insets are enlarged images of individual cells indicated by corresponding arrows at the indicated scale bar as 10 μm. H&E staining was conducted to analyze the lung inflammation and observed at the indicated scale bar as 100 μm.

(E) Body weights of mice among the above 7 groups were recorded. Each line represents data from one group.

(F) Snapshot of body weight on 3 days post infection in (E) was plotted. Data are represented as mean ± SEM; Mann-Whitney test was performed to compare treatment group with the SARS-CoV-2 control group. ns, no significance; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001. Data of (B), (C), (E), and (F) are represented as mean ± SEM. All experiments of (B) and (C) were repeated twice.

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Alpaca used in the immunization
  - hACE2 mice in the evaluating efficacy of Nbs *in vivo*.
  - BALB/c mice
  - Nude mice in spatial distribution of Nbs *in vivo*
  - Cell lines
  - Study approval
- **METHOD DETAILS**
  - SDS-PAGE and western blotting (WB)
  - ELISA analysis
  - Alpaca immunization
  - Construction of a phage library displaying Nbs
  - Panning Nb phage library and phage ELISA
  - Phage ELISA
  - Expression and purification of Nbs with different formats
  - Neutralization activity of Nbs against pseudovirus
  - Neutralization activity of Nbs against live SARS-CoV-2
  - Affinity determination by Bio-Layer Interferometry (BLI)
  - Epitope binning by BLI
  - Pharmacokinetics of Nbs *in vivo*
  - Spatial distribution of Nbs *in vivo*
  - Evaluating the efficacy of Nbs in SARS-CoV-2 infected hACE2 mice
  - Viral load measurement by quantitative RT-PCR
  - Immunofluorescence staining of SARS-CoV-2-infected cells in tissues
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

#### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2021.109869>.

#### ACKNOWLEDGMENTS

This work was supported by National Science Foundation of China (NSFC) (no. 81803414 and 31970149), the Major Research and Development Project (2018ZX10301406), Nanjing University-Ningxia University Collaborative Project (grant no. 2017BN04), Jiangsu Province Natural Science Foundation for Young Scholar (grant no. BK20170653), Key Natural Science Foundation of Jiangsu Province (grant no. ZDA2020014), Jiangsu Province “Innovative and Entrepreneurial talent” and Six Talent Peaks Project of Jiangsu Province, the Emergency Prevention and Control Capacity Program for New Severe Infectious Diseases of National Institute for Viral Disease Control and Prevention, and the 135 Strategic Program of Chinese Academy of Sciences, the Science and Technology Innovation Committee of Shenzhen Municipality (JCYJ2018 0228162229889).

#### AUTHOR CONTRIBUTIONS

X.W. conducted most experiments, analyzed the data, and wrote the manuscript draft. L.C. conducted all the neutralization experiments. B.H., L.Z., S.X., H.S., D.Z., H.Y., and W.N. provided technical assistance and did animal experiments. M.F., Y.L., P.Y., and Q.H. evaluated the efficacy of Nbs in SARS-CoV-2-infected transgenic hACE2 mice. Z.W. designed the study, directed

and financially supported the study, and revised the manuscript. All authors critically reviewed the draft manuscript and approved the final version.

#### DECLARATION OF INTERESTS

The authors declared no competing interests. X.W. and Z.W. are listed as inventors on a China patent (CN202110120326.8) related with the Nbs for the treatment of SARS-CoV-2 infection.

Received: March 3, 2021

Revised: July 8, 2021

Accepted: September 29, 2021

Published: October 6, 2021

#### REFERENCES

- Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020). The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* 583, 830–833.
- Baum, A., Fulton, B.O., Wloga, E., Copin, R., Pascal, K.E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020). Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science* 369, 1014–1018.
- Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020). Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. *Cell* 182, 73–84.e16.
- Cunningham, S., Piedra, P.A., Martinon-Torres, F., Szymanski, H., Brackeva, B., Dombrecht, E., Detalle, L., Fleurinck, C., Cunningham, S., Piedra, P.A., et al. (2020). Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir. Med.* 9, 21–32.
- Dai, L., and Gao, G.F. (2020). Viral targets for vaccines against COVID-19. *Nat. Rev. Immunol.* 21, 73–82.
- Detalle, L., Stohr, T., Palomo, C., Piedra, P.A., Gilbert, B.E., Mas, V., Millar, A., Power, U.F., Stortelers, C., Allosery, K., et al. (2015). Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. *Antimicrob. Agents Chemother.* 60, 6–13.
- Dong, J., Huang, B., Jia, Z., Wang, B., Gallolu Kankanamalage, S., Titong, A., and Liu, Y. (2020). Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity. *Emerg. Microbes Infect.* 9, 1034–1036.
- Gallo, O., Locatello, L.G., Mazzoni, A., Novelli, L., and Annunziato, F. (2020). The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. *Mucosal Immunol.* 14, 305–316.
- Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hamers, C., Songa, E.B., Bendahman, N., and Hamers, R. (1993). Naturally occurring antibodies devoid of light chains. *Nature* 363, 446–448.
- Hanke, L., Vidakovics Perez, L., Sheward, D.J., Das, H., Schulte, T., Moliner-Morro, A., Corcoran, M., Achour, A., Karlsson Hedestam, G.B., Hällberg, B.M., et al. (2020). An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. *Nat. Commun.* 11, 4420.
- Hart, T.K., Cook, R.M., Zia-Amirhosseini, P., Minthorn, E., Sellers, T.S., Mal-eef, B.E., Eustis, S., Schwartz, L.W., Tsui, P., Appelbaum, E.R., et al. (2001). Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. *J. Allergy Clin. Immunol.* 108, 250–257.
- Higgins, T.S., Wu, A.W., Illing, E.A., Sokoloski, K.J., Weaver, B.A., Anthony, B.P., Hughes, N., and Ting, J.Y. (2020). Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review. *Otolaryngol. Head Neck Surg.* 163, 682–694.



- Huo, J., Le Bas, A., Ruza, R.R., Duyvesteyn, H.M.E., Mikolajek, H., Malinauskas, T., Tan, T.K., Rijal, P., Dumoux, M., Ward, P.N., et al. (2020). Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. *Nat. Struct. Mol. Biol.* **27**, 846–854.
- Jähnichen, S., Blanchetot, C., Maussang, D., Gonzalez-Pajuelo, M., Chow, K.Y., Bosch, L., De Vriese, S., Serruys, B., Ulrichs, H., Vandeveld, W., et al. (2010). CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. *Proc. Natl. Acad. Sci. USA* **107**, 20565–20570.
- Jovčevska, I., and Muyldermans, S. (2019). The Therapeutic Potential of Nanobodies. *BioDrugs* **34**, 11–26.
- Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* **584**, 115–119.
- Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A., et al. (2020). Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. *bioRxiv*. <https://doi.org/10.1101/2020.06.17.153486>.
- Luo, F., Liao, F.L., Wang, H., Tang, H.B., Yang, Z.Q., and Hou, W. (2018). Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine. *Virology* **33**, 201–204.
- Ma, X., Zou, F., Yu, F., Li, R., Yuan, Y., Zhang, Y., Zhang, X., Deng, J., Chen, T., Song, Z., et al. (2020). Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. *Immunity* **53**, 1315–1330.e9.
- Nambulli, S., Xiang, Y., Tilston-Lunel, N.L., Rennick, L.J., Sang, Z., Klimstra, W.B., Reed, D.S., Crossland, N.A., Shi, Y., and Duprex, W.P. (2021). Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. *Sci. Adv.* **7**, eabh0319.
- Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature* **596**, 276–280.
- Prince, G.A., Hemming, V.G., Horswood, R.L., Baron, P.A., and Chanock, R.M. (1987). Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. *J. Virol.* **67**, 1851–1854.
- Pymm, P., Adair, A., Chan, L.J., Cooney, J.P., Mordant, F.L., Allison, C.C., Lopez, E., Haycroft, E.R., O'Neill, M.T., Tan, L.L., et al. (2021). Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. *Proc. Natl. Acad. Sci. USA* **118**, e2101918118.
- Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., Agudelo, M., Barnes, C.O., Gazumyan, A., Finkin, S., et al. (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437–442.
- Rogers, T.F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956–963.
- Schoof, M., Faust, B., Saunders, R.A., Sangwan, S., Rezelj, V., Hoppe, N., Boone, M., Billesbølle, C.B., Puchades, C., Azumaya, C.M., et al.; QCRG Structural Biology Consortium (2020). An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. *Science* **370**, 1473–1479.
- Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature* **584**, 120–124.
- Steele, S., Vandenbroucke, R.E., and Libert, C. (2016). Nanobodies as therapeutics: big opportunities for small antibodies. *Drug Discov. Today* **21**, 1076–1113.
- Taylor, A., Foo, S.S., Bruzzone, R., Dinh, L.V., King, N.J., and Mahalingam, S. (2015). Fc receptors in antibody-dependent enhancement of viral infections. *Immunol. Rev.* **268**, 340–364.
- Tirado, S.M., and Yoon, K.J. (2003). Antibody-dependent enhancement of virus infection and disease. *Viral Immunol.* **16**, 69–86.
- Van Heeke, G., Allosery, K., De Brabant, V., De Smedt, T., Detalle, L., and de Fougerolles, A. (2017). Nanobodies® as inhaled biotherapeutics for lung diseases. *Pharmacol. Ther.* **169**, 47–56.
- Van Roy, M., Ververken, C., Beirnaert, E., Hoefman, S., Kolkman, J., Vierboom, M., Breedveld, E., 't Hart, B., Poelmans, S., Bontinck, L., et al. (2015). The pre-clinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. *Arthritis Res. Ther.* **17**, 135.
- Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., and Tan, W. (2020). Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **323**, 1843–1844.
- Wu, X., Ma, X., Li, Y., Xu, Y., Zheng, N., Xu, S., Nawaz, W., and Wu, Z. (2019). Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells. *Antib. Ther.* **2**, 45–53.
- Wu, X., Li, Y., Huang, B., Ma, X., Zhu, L., Zheng, N., Xu, S., Nawaz, W., Xu, C., and Wu, Z. (2020a). A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo. *JCI Insight* **5**, e136855.
- Wu, Y., Li, C., Xia, S., Tian, X., Kong, Y., Wang, Z., Gu, C., Zhang, R., Tu, C., Xie, Y., et al. (2020b). Identification of Human Single-Domain Antibodies against SARS-CoV-2. *Cell Host Microbe* **27**, 891–898.e5.
- Xiang, Y., Nambulli, S., Xiao, Z., Liu, H., Sang, Z., Duprex, W.P., Schneidman-Duhovny, D., Zhang, C., and Shi, Y. (2020). Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. *Science* **370**, 1479–1484.
- Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273.
- Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schäfer, A., Reidy, J.X., Trivette, A., Nargi, R.S., et al. (2020). Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* **584**, 443–449.



STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Anti-human IgG conjugated with an IRDye 800CW	Rockland	Cat#926-32232
Anti-rabbit IgG conjugated with an IRDye 800CW	Rockland	Cat#925-32211
Goat anti-llama IgG (H+L) secondary antibody with HRP	Novus	Cat# NB7242
Anti-M13 bacteriophage antibody with HRP	Sino Biological	Cat#11973-MM05T-H
Rabbit anti-SARS-CoV-N IgG	Sino Biological	Cat#40143-R019
HRP-conjugated goat anti-rabbit IgG (H+L) antibody	Jackson ImmunoResearch	Cat#111-035-003
SARS-CoV/SARS-CoV-2 Nucleocapsid Antibody, Mouse mAb	Sino Biological	Cat#40143-MM05
SNB02	Y-Clone	Cat#YL2018-003
Nanobody against HSA (Nb <sub>H</sub> )	Abrev	Cat#AR2020-010
<b>Bacterial and virus strains</b>		
TG1 bacteria	Y-Clone	N/A
M13KO7 helper phage	Invitrogen	Cat#18311019
SARS-CoV-2 live virus of Beta/Shenzhen/SZTH-003/2020 for cell assay	Shenzhen Third People's Hospital	EPI_ISL_406594 at GISAID
SARS-CoV-2 pseudovirus and its variants	This Paper	N/A
SARS-CoV pseudovirus	This Paper	N/A
Mers-CoV Pseudovirus	This Paper	N/A
SARS-CoV-2 live virus for animal study	Wuhan Institute of Virology	IVCAS 6.7512
<b>Biological samples</b>		
Nb Phage library	This Paper	C9-Nb-lib
<b>Chemicals, peptides, and recombinant proteins</b>		
SARS-CoV-2 Spike protein (S1+S2 ECD, S)	Sino Biological	Cat#40589-V08B1
SARS-CoV-2 RBD protein	Sino Biological	Cat#40592-V08H
Freund's complete adjuvant	Sigma	Cat#F5881-10ML
Freund's incomplete adjuvant	Sigma	Cat#F5506-10M
3,3',5,5'-Tetramethylbenzidine	Sigma	Cat#54827-17-7
Ficoll-Paque Plus	GE	Cat#17-1140-02
TRIzol reagent	Life Technologies	Cat#15-596-018
KPL TrueBlue Peroxidase Substrates	SeraCare Life Sciences Inc.	Cat#5510-0030
10% neutral buffered formalin	Sigma	Cat# Z2902
Far infrared dye YF@750 SE	US EVERBRIGHT INC	YS0056
<b>Critical commercial assays</b>		
Anti-human Fc (AHC) biosensors	Fortebio	Cat#18-5060
AR2G biosensor	Fortebio	Cat#18-5092
Amino coupling kit	Fortebio	Cat#18-5095
RT-PCR Prime Script Kit	Takara	Cat#PR005B
<b>Experimental models: Cell lines</b>		
HEK293T-ACE2 cells	Yeasen Biotech	Cat# 41107ES0
Huh7 cells	ATCC	CCL-185

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
293T cells	ATCC	CRL-3216
293-F cells	Thermo Fisher Scientific	R79007
<b>Experimental models: Organisms/strains</b>		
Transgenic hACE2 mice (C57BL/6J)	GemPharmatech	Cat T037630
Alpaca	Y-Clone	AR-0019
BALB/c	Qing Long Shan Animal Center	QIs02-0202
Nude mice	Qing Long Shan Animal Center	QIs03-0102
<b>Oligonucleotides</b>		
TaqMan probe (5'-FAM- CAGGT GGAACCTCATCAGGAGATGC -MGB-3')	This paper	N/A
Primer of orf1ab gene of SARS-CoV-2 Forward: (5'- GTGARATGGTCATGTGTGGCGG -3')	This paper	N/A
Primer of orf1ab gene of SARS-CoV-2 Reverse: (5'- CARATGTTAAASACACTATTAGCATA -3')	This paper	N/A
<b>Recombinant DNA</b>		
pCDNA3.1-S encoding spike protein of variant coronavirus	This paper	N/A
pCDNA3.4 eukaryotic expression vector	Invitrogen	Cat#A14697
HIV-1 NL4-3 ΔEnv Vpr Luciferase Reporter Vector (pNL4-3.Luc.R-E-)	HIV AIDS Reagent Program	Cat#3418
phV1 phagemid plasmid	Y-Clone	N/A
pcDNA3.4-Nbs	This paper	N/A
<b>Software and algorithms</b>		
GraphPad Prism 8.01	GraphPad Software Inc.	<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a> ; RRID:SCR_002798
ImageJ		<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a> ; RRID: SCR_001935
Indigo imaging software	Berthold	<a href="https://www.berthold.com/en/bioanalytic/products/in-vivo-imaging-systems/nightowl-lb983/">https://www.berthold.com/en/bioanalytic/products/in-vivo-imaging-systems/nightowl-lb983/</a>
OriginPro 8.5 software	OriginLab	<a href="https://www.originlab.com/">https://www.originlab.com/</a> ; RRID:SCR_014212
<b>Others</b>		
96-well plates	Corning	Cat# 9018
Protein G	Thermo Fisher Scientific	Cat# 20399
Ni-NTA	Thermo Fisher Scientific	Cat#R901100

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Zhiwei Wu ([wzhw@nju.edu.cn](mailto:wzhw@nju.edu.cn)).

**Materials availability**

This study did not generate new unique reagents.

**Data and code availability**

- The data that support the findings of this study are available upon request from the lead contact.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Alpaca used in the immunization

An alpaca (Female, 2-3 years old, cat.# AR-0019) was purchased from Xuzhou Animal Center (Xuzhou, China). Animal experiments were done by veterinarian with the authorization of animal operation and in accordance with the China law for animal protection.

### hACE2 mice in the evaluating efficacy of Nbs *in vivo*.

A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630) were purchased from GemPharmatech Co., Ltd. (Nanjing, China). All of the hACE2 mice were handled in Biosafety Level 3 animal facilities in accordance with the recommendations for care and use of the Institutional Review Board of Wuhan Institute of Virology of the Chinese Academy of Sciences (Ethics Number: WIVA11202003).

### BALB/c mice

BALB/c (6-8 weeks of age, Female, cat.# QIs02-0202) was purchased from Qing Long Shan Animal Center (Nanjing, China). The BALB/c mice were kept in ventilated cages and given access to standard pellet feed and water *ad libitum* following Nanjing University Laboratory Animal center's standard operational procedures.

### Nude mice in spatial distribution of Nbs *in vivo*

Nude mice (18-22 g, female, QIs03-0102) were purchased from Qing Long Shan Animal Center (Nanjing, China). The nude mice were kept in ventilated cages and given access to standard pellet feed and water *ad libitum* following Nanjing University Laboratory Animal center's standard operational procedures.

### Cell lines

293T cells (ATCC), HEK293T-ACE2 cells (Cat# 41107ES0, Yeasen Biotech) and Huh7 cells (ATCC) were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) containing 10% Fetal bovine serum, 100 U/mL penicillin and 2 mM L-glutamine and were incubated at 37°C in 5% CO<sub>2</sub> setting. 293-F cells (Thermo Fisher Scientific) were cultured in Expi293TM Expression Medium and were incubated in a 37°C incubator and 8% CO<sub>2</sub> setting on an orbital shaker platform at 130 rpm according to the manufacturer's instructions.

### Study approval

The study and the protocol for this research were approved by the Center for Public Health Research, Medical School, Nanjing University. All animal experimental procedures without infection were approved by the Committee on the Use of Live Animals by the Ethics Committee of Nanjing University. All of the animals infected by SARS-CoV-2 were handled in Biosafety Level 3 animal facilities in accordance with the recommendations for care and use of the Institutional Review Board of Wuhan Institute of Virology of the Chinese Academy of Sciences (Ethics Number: WIVA11202003). All the authors declare their compliance with publishing ethics.

## METHOD DETAILS

### SDS-PAGE and western blotting (WB)

The purified protein or antibody was separated by electrophoresis in a 7.5%–12% polyacrylamide gel. The separated protein or antibody was revealed either using Coomassie blue or transferred to PVDF membrane for WB analysis under reducing or non-reducing conditions with  $\beta$ -mercaptoethanol. The membrane was first blocked and then incubated overnight at 4°C or 37°C for one hour with diluted plasma or antibody, followed by incubation with the secondary antibody of either anti-human IgG or anti-rabbit IgG conjugated with an IRDye 800CW (cat.# 926-32232, Rockland). Protein bands were visualized using the Odyssey Image System (Li-COR).

### ELISA analysis

Anti-sera titer and antibody characterization or antibody quantification *in vivo* were examined by ELISA as reported in our previously published method (Wu et al., 2019) with modifications. In brief, the protein was coated to high protein-binding ELISA plates (Corning) at a concentration of 0.5  $\mu$ g/ml, 100  $\mu$ L per well at 37°C for 2 hours (h) or 4°C overnight. After washing, blocking buffer with 5% non-fat milk in PBS was added and incubated at 37°C for 1 h. After washing 2-4 times, 100  $\mu$ L serially diluted anti-serum or purified antibody was added and incubated at 37°C for 1.5 h. Following washing, goat anti-llama IgG (H+L) secondary antibody with HRP (Novus, cat.# NB7242, 1:10000 dilution) was added and incubated at 37°C for 1 h. Accordingly, 3,3',5,5'-Tetramethylbenzidine (TMB, Sigma) substrate was added at 37°C for 10 minutes (min); and the reaction was stopped by adding 10  $\mu$ L 0.2 M H<sub>2</sub>SO<sub>4</sub>. The optical densities at 450 nm were measured using the Infinite 200 (Tecan, Ramsey, MN, USA). Antibody titers were defined as the highest dilution when the diluted serum produced at least 2.1-fold optical density readout as compared to the control serum sample at the same dilution.

### Alpaca immunization

250  $\mu$ g the extracellular domain of SARS-CoV-2 spike protein fused with His tag (S1+S2 ECD, S, cat.# 40589-V08B1, Sino Biological) was emulsified with 250  $\mu$ L Freund's complete adjuvant (F5881-10ML, Sigma) to immunize an alpaca (Female, 2-3 years old, Y-Clone, China). On day 14 and 28, the alpaca was boosted twice with 250  $\mu$ g S protein in 250  $\mu$ L Freund's incomplete adjuvant (F5506-10ML, Sigma). One week following the 2<sup>nd</sup> immunization, we collected the blood samples to measure anti-serum titer. One week after the 3<sup>rd</sup> immunization, 100 mL of blood was collected to measure anti-serum titer and construct a phage library displaying Nb.

### Construction of a phage library displaying Nbs

Nb phage library was constructed following our previously published method with some modifications (Wu et al., 2020a). In brief, PBMCs were isolated from 100 mL blood of immunized alpaca using a lymphocyte separation solution (cat.# 17-1140-02, Ficoll-Paque Plus, GE). RNA was extracted and reverse transcribed into cDNA by oligo (dT) and random hexamers as primers using the TRIzol kit (cat.# 15596018, Life Technologies), following manufacturer's instruction. The alpaca Nb gene was amplified with the combination of primers and cloned into phV1 phagemid plasmid (Y-Clone, Ltd., China) to transform TG1 bacteria.

### Panning Nb phage library and phage ELISA

Affinity selection for S-binding recombinant phages was performed as previously reported with the following modifications (Jähnchen et al., 2010). The Nb-phagemid-transformed bacteria were rescued with M13KO7 helper phage (cat.# 18311019, Invitrogen), and precipitated with PEG/NaCl. The phage Nb antibody library was enriched three times with 50  $\mu$ g/ml of S protein. The enriched phage was eluted, transformed, and selected for the monoclonal phage to be evaluated by phage ELISA.

### Phage ELISA

200 ng S or RBD protein in coating buffer (pH 9.6) was used to coat 96-well plates (cat.# 9018, Corning) at 4°C overnight. After washing, the plates were blocked with blocking buffer (3% BSA in PBST) for 1 h at 37°C, and then incubated with library phages or single clone phage in bacterial supernatant at 4°C for 1.5 h. After washing, an anti-M13 bacteriophage antibody with HRP (1:10000 dilution, cat.# 11973-MM05T-H, Sino Biological) was added and incubated at 37°C for 1 h. Accordingly, TMB substrate (Sigma) was added at 37°C for 10 min; 10  $\mu$ L 0.2 M H<sub>2</sub>SO<sub>4</sub> was added to stop the reaction. Optical densities were measured at 450 nm using the Infinite 200 (Tecan, Ramsey, MN, USA). Clones with readout at 450 nm > 0.5 were sequenced.

### Expression and purification of Nbs with different formats

To facilitate the purification and prolong the half-life of the Nb antibody, the Fc1 gene (CH2-CH3) of the human monoclonal antibody was fused with the Nb gene (Nb-Fc), as our previously published method (Wu et al., 2020a). In addition, to improve the activity of Nb, we constructed Nbs with various configurations wherein (GGGG)<sub>3</sub> linkers were introduced between Nbs in dimeric and trimeric forms. Nanobody specific to HSA, Nb<sub>H</sub> (Table S1, Abrev biotechnology, China), was developed from an alpaca receiving the immunization of HSA. To facilitate protein purification, a 6xHis-tag was fused to the N terminus of the Nbs of monomeric, dimeric or trimeric configuration. The Nbs with different configurations were finally cloned into the pcDNA3.4 eukaryotic expression vector (Invitrogen), which were transfected into 293F cells to produce Nbs with different configurations. Nb fused with Fc, or His tag was purified using Protein G (cat.# 20399, Thermo Scientific) and Ni-NTA (cat.# R901100, Thermo Fisher Scientific), respectively.

### Neutralization activity of Nbs against pseudovirus

Pseudovirus neutralization assay was performed as previously described with the following modifications (Ju et al., 2020). SARS-CoV-2, SARS-CoV, and MERS-CoV pseudoviruses were produced by co-transfection of pNL4-3.Luc.R-E-, an HIV-1 NL4-3 luciferase reporter vector that contains defective Nef, Env and Vpr (HIV AIDS Reagent Program), and pcDNA3.1 (Invitrogen) expression vectors encoding the respective spike proteins (GenBank: MN988668.1 for SARS-CoV-2, AAP13567.1 for SARS-CoV, AFS88936.1 for MERS-CoV) into 293T cells (ATCC). Pseudovirus containing supernatants were collected after 48 h, and viral titers were measured by luciferase assay in relative light units (Bright-Glo Luciferase Assay Vector System, Promega Biosciences). S genes of SARS-CoV-2 variants with indicated mutations based on the human codon optimized S gene (GenBank: MN988668.1) were synthesized, and the corresponding pseudoviruses were produced following above protocol. For neutralization assay, SNB02 (Nb-Fc) against SFTSV (Wu et al., 2020a) served as a control. Neutralization assays were performed by incubating pseudoviruses with serial dilutions of purified Nbs or serum at 37°C for 1 h. HEK293T-ACE2 cells (cat.# 41107ES03, Yeasen Biotech Co., Ltd. China) for SARS-CoV-2 and SARS-CoV, Huh7 cells (ATCC) for MERS-CoV (approximately 1.5  $\times$  10<sup>4</sup> per well) were then added in duplicate to the virus-antibody mixture. Half-maximal inhibitory dilution (ND<sub>50</sub>) of the evaluated sera or half-maximal inhibitory concentrations (IC<sub>50</sub>) of the evaluated Nbs were determined by luciferase activity 48 h after exposure to virus-antibody mixture, and analyzed by GraphPad Prism 8.01 (GraphPad Software Inc.).

### Neutralization activity of Nbs against live SARS-CoV-2

SARS-CoV-2 focus reduction neutralization test was performed in a certified Biosafety Level 3 laboratory, as previously described with the following modifications (Ju et al., 2020). Briefly, a clinical isolate (Beta/Shenzhen/SZTH-003/2020, EPI\_ISL\_406594 at

GISAID) previously obtained from a nasopharyngeal swab of an infected patient was used for the analysis. Serial concentrations of Nbs were mixed with 75  $\mu$ L of SARS-CoV-2 ( $8 \times 10^3$  focus forming unit/ml, FFU/ml) in 96-well microwell plates and incubated at 37°C for 1 h. The mixtures were then transferred to 96-well plates seeded with Vero E6 cells and incubated at 37°C for 1 h. Next, the inoculums were removed prior to the addition of the overlay media (100  $\mu$ L MEM containing 1.6% carboxymethylcellulose, CMC) and the plates were then incubated at 37°C for 24 h. Cells were fixed with 4% paraformaldehyde solution for 30 min, and then the overlays were removed. Cells were permeabilized with 0.2% Triton X-100 and incubated with cross-reactive rabbit anti-SARS-CoV-N IgG (Sino Biological, Inc) for 1 h at room temperature before the addition of HRP-conjugated goat anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch) and further incubated at room temperature. The foci were stained with KPL TrueBlue Peroxidase substrates (SerCare Life Sciences Inc.) and were counted with an EliSpot reader (Cellular Technology Ltd.).

### Affinity determination by Bio-Layer Interferometry (BLI)

Affinity assays were performed on a ForteBio OctetRED 96 biolayer interferometry instrument (Molecular Devices ForteBio LLC, Fremont, CA) at 25°C with shaking at 1,000 rpm. To measure the affinity of Nbs with human Fc tag, anti-human Fc (AHC) biosensors (cat.# 18-5060, ForteBio) were hydrated in water for 30 min prior to 60 s (sec) incubation in a kinetic buffer (PBS, 0.02% (v/v) Tween-20, pH 7.0). Either Nb-Fc in cell supernatant or purified Nb-Fcs were loaded in a kinetic buffer for 200 s prior to baseline equilibration for 200 s in a kinetic buffer. Association of SARS-CoV-2 RBD in a two-fold dilution series from 20 nM to 2.5 nM was performed prior to dissociation for 180 s. To measure the affinity of Nbs without Fc tag, RBD protein was coupled to AR2G biosensor (cat.# 18-5092, ForteBio) via BLI instrument according to the instructions of the amino coupling kit. Association of Nbs in a serial dilution was performed prior to dissociation for 180 s. After each cycle, the biosensors were regenerated via 3 short pulses of 5 s each of 100 mM pH 2.7 glycine-HCL followed by running buffer. The data were baseline subtracted before fitting performed using a 1:1 binding model and the ForteBio data analysis software.  $K_D$ ,  $K_a$  and  $K_d$  values were evaluated with a global fit applied to all data.

### Epitope binning by BLI

The epitope binning assay was performed with AR2G biosensor (cat.# 18-5092, ForteBio) following the manufacturer's protocol 'intandem assay' as previously reported (Rogers et al., 2020). After loading the RBD protein, a saturating concentration of antibody or Nbs (50  $\mu$ g/ml) as the first antibody was added for 300 s following with the baseline step with 30 s immersion in 0.02% PBST. The second competing concentration of antibody or Nb (50  $\mu$ g/ml) was then added for 300 s to measure binding in the presence of the first saturating antibody or Nb. GraphPad was used to illustrate the time-response course of two antibodies binding to RBD protein.

### Pharmacokinetics of Nbs *in vivo*

Purified Nbs were injected intranasally (*i.n.*), intraperitoneally (*i.p.*) or intravascularly into BALB/c (Qing Long Shan Animal Center, Nanjing, China) at a dose of 10-20 mg/kg. ELISA was used to measure the serum concentration of Nbs. The  $T_{1/2}$  of Nbs was computed as  $\ln(2)/k$ , where  $k$  is a rate constant expressed reciprocally of the x axis time units by the one phase decay equation or plateau followed one phase decay in the GraphPad software.

### Spatial distribution of Nbs *in vivo*

Nbs were labeled with far infrared dye YF®750 SE (US EVERBRIGHT INC, YS0056) (named as Nbs-YF750). Purified Nbs-YF750 were injected *i.n.*, *i.p.* or *i.v.* into nude mice (18-22 g, Qing Long Shan Animal Center, Nanjing, China) at a dose of 10-20 mg/kg. Images were observed at Ex:740 nm/Em:780 nm by NightOWL LB 983 (Berthold, Germany) at the indicated time point. Images were analyzed using Indigo imaging software Ver. A 01.19.01.

### Evaluating the efficacy of Nbs in SARS-CoV-2 infected hACE2 mice

A total of 31 8-week-old male transgenic hACE2 mice (C57BL/6J) (cat.# T037630, GemPharmatech Co., Ltd., Nanjing, China) were challenged with  $1 \times 10^5$  PFU SARS-CoV-2 (IVCAS 6.7512; Zhou et al., 2020) per mouse as previously reported (Ma et al., 2020) with following modifications. The mice were split into seven groups ( $n = 3-5$ ) for either prophylactic or therapeutic evaluation, as described in Figure 5A. Mice without any challenge and treatment served as blank control (No SARS-CoV-2,  $n = 4$ ). Mice challenged with SARS-CoV-2 were taken as infection control (SARS-CoV-2,  $n = 5$ ). 250  $\mu$ g SNB02 (Y-Clone, China), an anti-SFTSV antibody constructed by Nb fused with human Fc1 (Nb-Fc) (Wu et al., 2020a), was intranasally injected 1 h after infection and served as an isotype treated control (Isotype). For the prophylactic group, mice were intranasally injected with Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> at a dose of 250  $\mu$ g/mouse (average of 10 mg/kg) 24 h before infection (Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> -24h,  $n = 5$ ). For the therapeutic group, mice were intranasally injected with N Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> at a dose of 250  $\mu$ g/mouse (average of 10 mg/kg) 1 h or 24 h after infection (named as Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> 1h and Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> 24 h,  $n = 5$ , respectively). As a comparison, Nb<sub>15</sub>-Fc at a dose of 250  $\mu$ g/mouse (average of 10 mg/kg) was intranasally injected 1 h after infection (Nb<sub>15</sub>-Fc 1 h). Body weight of every mouse was measured daily. Transgenic hACE2 mice typically clear virus within five days after SARS-CoV-2 and viral RNA copies reached a peak at 3 dpi (Bao et al., 2020). Accordingly, the mice were sacrificed at 3 days post infection (dpi), and the lungs were collected for viral load determination and tissue sections for hematoxylin and eosin (H&E) and immunofluorescence staining.



### Viral load measurement by quantitative RT-PCR

Viral load was detected by quantitative real-time PCR (qRT-PCR) on RNA extracted from the supernatant of lung homogenates as described previously (Cao et al., 2020). Briefly, lung homogenates were prepared by homogenizing perfused whole lung using an electric homogenizer. The supernatant was collected, and total RNA was extracted. Each RNA sample was reverse transcribed to 50  $\mu$ L cDNA with RT-PCR Prime Script Kit (Takara). The cDNA (5  $\mu$ l) was used in a 25  $\mu$ L qRT-PCR reaction with the TaqMan Universal PCR Master Mix (Life Technologies), a TaqMan probe (5'-FAM– CAGGTGGAACCTCATCAGGAGATGC –MGB-3'), and primers designed to target the orf1ab gene of SARS-CoV-2 (5'- GTGARATGGTCATGTGTGGCGG –3' and 5'- CARATGTTAAASACACTATTAG CATA –3'). The samples were run in triplicate on an ABI 7900 Real-Time System (Applied Biosystems, Thermo Fisher Scientific). The following cycling conditions were used: 1 cycle of 50°C for 2 min, 1 cycle of 95°C for 10 min, and 40 cycles of 95°C for 15 s and 58°C for 1 min. The virus titer was determined by comparison with a standard curve generated using RNA extracted from a serially diluted reference viral stock. All experiments were performed in a Biosafety Level 3 facility.

### Immunofluorescence staining of SARS-CoV-2-infected cells in tissues

Lung tissues were immersed in 10% neutral buffered formalin (cat.# Z2902, Sigma) for 24 h. After the formalin fixation, the tissues were placed in 70% ethanol (Merck) and subsequently embedded with paraffin. Tissue sections (4- $\mu$ m thick) were used for immunofluorescence staining for SARS-CoV-2 detection using the Coronavirus nucleocapsid antibody (cat. 40143-MM05, Sino Biological). Images were obtained by OLYMPUS IX73 using HCLImage Live (  $\times$  64) software and analyzed by ImageJ (NIH).

### QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analyses were performed using GraphPad Prism 8.01 software (GraphPad) or OriginPro 8.5 software (OriginLab). ANOVA or Mann-Whitney test was performed for group comparisons.  $p < 0.05$  was considered as statistically significant with mean  $\pm$  SEM or mean  $\pm$  SD. All of the statistical details of experiments can be found in the figure legends.


**Cell Reports, Volume 37**

**Supplemental information**

**A potent bispecific nanobody  
protects hACE2 mice against SARS-CoV-2  
infection via intranasal administration**

**Xilin Wu, Lin Cheng, Ming Fu, Bilian Huang, Linjing Zhu, Shijie Xu, Haixia Shi, Doudou Zhang, Huanyun Yuan, Waqas Nawaz, Ping Yang, Qinxue Hu, Yalan Liu, and Zhiwei Wu**

- 1 **This file includes:**
- 2 Supplemental Figures 1 to 7
- 3 Supplemental Table 1 to 3
- 4




- 5
- 6 **Supplemental Figure 1. Characterization of anti-sera specific for SARS-CoV-2. Related to Figure**
- 7 **1. (A)** The experimental schedule for immunization. The titer of anti-sera specific for SARS-CoV-2 S
- 8 protein **(B)** and RBD protein **(C)** was evaluated one week after the immunization in alpaca receiving
- 9 SARS-CoV-2 spike protein, respectively. The titer of the third anti-serum was indicated as blue line.
- 10 The blue # indicates the anti-serum titer after the third immunization. 3<sup>rd</sup> anti-serum and 2<sup>nd</sup> anti-serum
- 11 represent the anti-sera collected from alpaca one week after the 3<sup>rd</sup> and 2<sup>nd</sup> immunization. Blank serum
- 12 represents the alpaca serum collected before immunization, which was taken as a negative control. **(D)**
- 13 Neutralization potency of the immunized alpaca's serum against pseudotyped SARS-CoV-2 was
- 14 detected. ND<sub>50</sub>: half-maximal serum neutralization dilution titer. Titer and ND<sub>50</sub> were indicated. Data of
- 15 B-D represent as mean ± SEM. All experiments of B-D were repeated twice.
- 16
- 17

A

The summary of C9-Nb library

Name	Library size	Sequencing clone	Sequence results	In frame clone	Diversity	In frame rate
C9-Nb-lib	$2.0 \times 10^9$	25	25	24	24/24 100%	24/25 96%




18

19 **Supplemental Figure 2. The construction and biopanning of C9-Nb library. Related to Figure 1.**

20 (A) The table summary of C9-Nb library, wherein phage displayed Nb of PBMC from alpaca receiving  
 21 three times immunization of SARS-CoV-2 S protein. (B) The binding of the phage library with S via  
 22 phage ELISA. Lib is the phage library of C9-Nb; 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> are the phage library after panning on  
 23 1 round, 2 rounds, and 3 rounds of S protein enrichment, respectively. (C) Single clone of phages from  
 24 the C9-Nb library after the second and third enrichment of SARS-CoV-2 S were analyzed by phage  
 25 ELISA. One dot represents the supernatant binding of one clone. Positive rate was indicated.

26

27



28

29 **Supplemental Figure 3. Characterization of Nb-Fc. Related to Figure 1.** (A) The diagram of Nb-Fc,

30 constituted by Nb fusing with human Fc1. (B) 21 various Nb-Fcs binding with S and RBD protein

31 identified by ELISA. Grey dot represents negative control. Green dots represent the specific binding

32 with S protein. Blue dots represent the double binding with S and RBD protein. (C) Representative

33 binding curve of Nb-Fcs with RBD tested by BLI. (D) The table summary of 21 Nb-Fcs binding with

34 RBD tested by BLI. (E) The cell supernatants of 21 various Nb-Fcs were tested for neutralization


35 against SARS-CoV-2 infection, the cell supernatant displaying outstanding neutralizing curve was

36 labeled as the color-coded curve. Data of B represent as mean  $\pm$  SEM. All experiments of B-E were

37 repeated twice

38






39

40 **Supplemental Figure 4. Characterization of purified Nb-Fcs. Related to Figure 1.** (A) Purified Nb-  
 41 Fcs binding with RBD identified by ELISA. Data represent as mean  $\pm$  SEM. (B) RBD protein under  
 42 reducing condition (R) or non-reducing condition (NR) was detected by WB with Nb<sub>15</sub>-Fc, Nb<sub>22</sub>-Fc and  
 43 Nb<sub>31</sub>-Fc. Kinetic binding curve of RBD with Nb<sub>15</sub>-Fc (C), Nb<sub>22</sub>-Fc (D) and Nb<sub>31</sub>-Fc (E), respectively.  
 44 Binding curves are colored black, and fit of the data to a 1:1 binding model is colored red.

45

46

Fig. S5



47

48 **Supplemental Figure 5. Epitope analysis of Nb-Fcs by BLI. Related to Figure 1.** RBD protein was

49 coated on the sensor, Nb<sub>15</sub>-Fc (A), Nb<sub>22</sub>-Fc (B) or Nb<sub>31</sub>-Fc(C) as the first antibody was added to bind

50 for 300 s following with the baseline step with 30 s immersion in 0.02% PBST. The second competing


51 concentration of Nb (50 µg/ml) was then added for 300 sec to measure binding in the presence of the

52 first saturating Nb.

53


54

55



56

57 **Supplemental Figure S6. Characterizing the potency of neutralization against authentic**  
 58 **SARS-CoV-2 conferred by Nb-Fcs. Related to Figure 1.** The neutralization potency of Nb<sub>15</sub>-Fc  
 59 (A), Nb<sub>22</sub>-Fc (B), Nb<sub>31</sub>-Fc(C), SNB02 (isotype control antibody) (D) was detected based on  
 60 authentic SARS-CoV-2 plaque reduction neutralization test. The raw data was depicted. (E) A table  
 61 summary authentic SARS-CoV-2 neutralization potencies of Nb-Fcs.



62

63 **Supplemental Figure 7. Kinetic binding curve of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> with MSA. Related to Figure 5.**

64 Kinetic binding curve of Nb<sub>15</sub>-Nb<sub>H</sub>-Nb<sub>15</sub> at the concentration of 300 nM, 100nM, 33.3 nM, 11.1nM,

65 3.7nM and 1.2 nM with MSA by BLI. Binding curves are colored black, and fit of the data to a 1:1

66 binding model is colored red.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

**Supplemental Table 1. Summary of CDR sequences of positive Nb clones. Related to Figure 1.**

ID	CDR1	CDR2	CDR3
<b>Nb<sub>1</sub>-Fc</b>	GNIFSIYT	VTSGGST	N-----ARLFDPGY
<b>Nb<sub>2</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSRLRDCLVNELYNY
<b>Nb<sub>4</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNELYNY
<b>Nb<sub>5</sub>-Fc</b>	GFTWNYHA	ISSSGSTT	AAPHSGSVCPR--WAEYYGVDH
<b>Nb<sub>7</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNEAYNY
<b>Nb<sub>9</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGGRLRGCLVNDLYNY
<b>Nb<sub>12</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNDLYNY
<b>Nb<sub>13</sub>-Fc</b>	GGTLASFA	ITNSGST	N-----TFHY
<b>Nb<sub>14</sub>-Fc</b>	GGTLASFA	ISSSGGST	TARPSLWAVVAGCPLDQNTYFS
<b>Nb<sub>15</sub>-Fc</b>	GGTLASFA	ISSSGST	AG-VVHDVQAM--CVMNP-WGS
<b>Nb<sub>19</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNDVYNY
<b>Nb<sub>22</sub>-Fc</b>	GGTLASFA	IDVINRA	AAHFVPPGSRLRGCLVNELYNY
<b>Nb<sub>24</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPEsRLRGCLVNELYNY
<b>Nb<sub>25</sub>-Fc</b>	GGTLASFA	ITSRRDT	YG-----QDVLGQIY
<b>Nb<sub>27</sub>-Fc</b>	GGTLASFA	ITSGGST	TT-----AGSWQGDY
<b>Nb<sub>28</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPEsRLRGCLVNEAYNY
<b>Nb<sub>29</sub>-Fc</b>	GGTLASFA	ISSRSFT	YG-----QDILGQIY
<b>Nb<sub>30</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSRLRGCLVNELYNY
<b>Nb<sub>31</sub>-Fc</b>	GGTLASFA	INIINRP	AAHFVPPGSRLGGCLVNELYNY
<b>Nb<sub>33</sub>-Fc</b>	GGTLASFA	INIINRT	AAHFVPPGSFRGCSVNELYNY
<b>Nb<sub>34</sub>-Fc</b>	GGTLASFA	INIINRP	AAHFVPPGSRLGGCLVNELYNY
<b>Nb<sub>H</sub></b>	GFILDYYA	IDSSGGTT	AAGGDLGVGQCSTWVRAYDY

96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111



112  
113  
114

**Supplemental Table 2. Summary of Nbs inhibiting SARS-CoV-2 variants. Related to Figure 1.**

Variants	Nb <sub>15</sub> -Fc ( mean±sd µg/ml )			Nb <sub>22</sub> -Fc ( mean±sd µg/ml )			Nb <sub>31</sub> -Fc ( mean±sd µg/ml )			Nb <sub>15</sub> -Nb <sub>H</sub> -Nb <sub>15</sub> ( mean±sd µg/ml )		
	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>90</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>90</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>90</sub>	IC <sub>50</sub>	IC <sub>80</sub>	IC <sub>90</sub>
WT	0.0008±0.0001	0.0019±0.0004	0.0033±0.0012	0.0016±0.0001	0.0046±0.0012	0.0086±0.0033	0.0023±0.0004	0.0083±0.0019	0.0183±0.0059	0.0004±0	0.0012±0.0004	0.0018±0.0009
Q321L	0.0009±0.0004	0.0023±0.0007	0.0039±0.0008	0.0014±0.0003	0.0042±0.0009	0.0079±0.0019	0.002±0.0005	0.0065±0.0017	0.0133±0.0033	0.001±0.0001	0.0022±0.0004	0.0034±0.0009
V341I	0.0007±0.0002	0.0026±0.0005	0.0059±0.0019	0.0017±0.0005	0.0042±0.0007	0.007±0.001	0.0028±0.0004	0.0087±0.0024	0.0169±0.0058	0.0011±0.0001	0.0027±0.0009	0.0047±0.0022
A348T	0.001±0.0002	0.0023±0.0003	0.0036±0.0005	0.0019±0.0008	0.0046±0.0012	0.0076±0.0016	0.0029±0.0001	0.0088±0.0013	0.0176±0.0032	0.0008±0.0002	0.0014±0.0001	0.0019±0.0004
N354D	0.0008±0.0002	0.0022±0.0002	0.0041±0.001	0.0013±0.0003	0.0033±0.0005	0.0056±0.0012	0.0019±0.0001	0.0068±0.0018	0.0145±0.0051	0.0006±0.0002	0.0016±0.0006	0.0032±0.0013
S359N	0.0011±0.0001	0.0026±0.0003	0.0043±0.0006	0.0016±0.0003	0.0037±0.0005	0.0061±0.0008	0.002±0.0005	0.0064±0.0012	0.0129±0.0037	0.0008±0.0002	0.0017±0.0002	0.0025±0.0005
V367F	0.0007±0.0001	0.002±0.0002	0.0036±0.0004	0.0011±0.0003	0.0033±0.0003	0.0062±0.0004	0.0021±0.0006	0.0095±0.0017	0.0237±0.0022	0.0005±0	0.0013±0.0001	0.0026±0.0006
K378R	0.0007±0.0002	0.0024±0.0003	0.0046±0.0001	0.0012±0.0002	0.0028±0.0003	0.0045±0.0005	0.0013±0.0001	0.004±0.0004	0.0079±0.0017	0.0008±0.0002	0.002±0.0004	0.0033±0.0006
R408I	0.0007±0.0002	0.002±0.0007	0.0035±0.0016	0.001±0.0001	0.0027±0.0003	0.0047±0.0009	0.0014±0.0002	0.0038±0.001	0.0069±0.0026	0.0007±0.0001	0.0014±0.0002	0.002±0.0005
Q409E	0.0005±0.0001	0.0014±0	0.0026±0.0002	0.0009±0.0003	0.0022±0.0007	0.0036±0.0011	0.0009±0.0001	0.0029±0.0004	0.0057±0.0007	0.0007±0.0002	0.0014±0.0002	0.0021±0.0003
K458R	0.0009±0.0003	0.0025±0.0002	0.0047±0.0006	0.0013±0.0001	0.0041±0.0014	0.008±0.0036	0.0025±0.0003	0.0068±0.0013	0.0128±0.004	0.0008±0.0002	0.0018±0.0003	0.0029±0.0004
G476S	0.0006±0.0002	0.0015±0.0004	0.0025±0.0006	0.0013±0.0006	0.0034±0.0011	0.006±0.0013	0.0015±0.0001	0.0049±0.0008	0.0101±0.0023	0.0003±0.0001	0.0009±0.0002	0.0014±0.0003
V483A	0.0006±0.0001	0.0017±0.0005	0.0031±0.0011	0.0015±0.0003	0.0039±0.0008	0.0069±0.0026	0.0027±0.001	0.0093±0.0018	0.0206±0.0027	0.0005±0.0001	0.0013±0	0.0022±0.0002
Y508H	0.0005±0.0001	0.0023±0.0003	0.0053±0.001	0.0013±0.0002	0.0035±0.0007	0.006±0.0015	0.0018±0.0005	0.0068±0.0007	0.0157±0.0047	0.0008±0.0001	0.0019±0.0006	0.0033±0.0016
H519P	0.0008±0.0001	0.0023±0.0002	0.0041±0.0005	0.0011±0.0002	0.0033±0	0.006±0.0004	0.0014±0.0003	0.005±0.0004	0.0107±0.0032	0.0007±0.0002	0.0016±0.0001	0.0025±0.0002
D614G	0.0007±0.0001	0.002±0.0002	0.0035±0.0007	0.0012±0.0005	0.0033±0.0005	0.0059±0.0003	0.0015±0.0004	0.0039±0.001	0.0067±0.0016	0.0006±0.0001	0.0015±0.0005	0.0026±0.001
A435S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0007±0.0001	0.0015±0.0003	0.0024±0.0006
I472V	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0006±0.0001	0.0014±0.0003	0.0023±0.0006
E484K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	>1.000	>1.000	>1.000
N501Y	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.0007±0.0002	0.002±0.0005	0.0042±0.0013

Note: N/A, no test

115  
116  
117  
118  
119  
120  
121

122  
123  
124

**Supplemental Table 3.** Summary of RBD binding with Nb<sub>15S</sub> in different conditions. **Related to Figure 5.**

Sample ID	Condition	Conc. (nM)	Response	KD (M)	Ka(1/Ms)	Kd(1/s)	RMax	Full R <sup>2</sup>
Nb <sub>15</sub> -Nb <sub>H</sub> -Nb <sub>15</sub>	WT	133.3	0.3806	<1.0E-12	3.44E+05	<1.0E-07	0.3687	0.9676
	Aero	133.3	0.2139	9.92E-09	4.11E+04	4.08E-04	0.3277	0.9957
	37 °C	133.3	0.3756	<1.0E-12	1.89E+05	<1.0E-07	0.374	0.9948
	50 °C	133.3	0.3903	5.78E-11	2.11E+05	1.22E-05	0.3849	0.996
	60 °C	133.3	0.4048	5.57E-10	1.91E+05	1.06E-04	0.402	0.9986
	70 °C	133.3	0.3775	2.52E-10	1.63E+05	4.10E-05	0.3801	0.9989
	80 °C	133.3	0.3199	5.64E-09	5.85E+04	3.30E-04	0.4193	0.9994
	90 °C	133.3	0.1078	1.02E-08	2.90E+04	2.95E-04	0.211	0.9978
Nb <sub>15</sub> -Fc	WT	62.5	0.8028	<1.0E-12	6.98E+05	<1.0E-07	0.7814	0.9824
	Aero	62.5	0.3398	2.79E-10	5.05E+04	1.41E-05	0.7387	0.999
	37 °C	62.5	0.8136	<1.0E-12	4.34E+05	<1.0E-07	0.804	0.9946
	50 °C	62.5	0.853	<1.0E-12	4.11E+05	<1.0E-07	0.848	0.9976
	60 °C	62.5	0.7989	4.38E-11	4.11E+05	1.80E-05	0.7944	0.9979
	70 °C	62.5	0.6126	4.95E-09	8.87E+04	4.39E-04	0.956	0.9995
	80 °C	62.5	0.2077	1.98E-08	4.16E+04	8.26E-04	0.557	0.9983
	90 °C	62.5	0.1088	4.12E-08	2.76E+04	1.14E-03	0.4281	0.9978
3xNb <sub>15</sub>	WT	133.3	0.3769	<1.0E-12	6.20E+05	<1.0E-07	0.3637	0.8833
	Aero	133.3	0.184	<1.0E-12	2.55E+04	<1.0E-07	0.3816	0.9946
	37 °C	133.3	0.3667	<1.0E-12	4.01E+05	<1.0E-07	0.3578	0.9563
	50 °C	133.3	0.3588	<1.0E-12	3.96E+05	<1.0E-07	0.3507	0.9583
	60 °C	133.3	0.3715	<1.0E-12	3.49E+05	<1.0E-07	0.3635	0.9717
	70 °C	133.3	0.2294	<1.0E-12	2.78E+04	<1.0E-07	0.4508	0.9975
	80 °C	133.3	0.2748	4.97E-10	4.53E+04	2.25E-05	0.4052	0.9994
	90 °C	133.3	0.1294	4.87E-09	5.21E+04	2.54E-04	0.1778	0.9968

125  
126  
127  
128  
129